- Gamida Cell Announces Results from Phase 3 Study of Omidubicel to be Presented at the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT)
- Gamida Cell Announces $75 Million Financing with Highbridge Capital Management
- Gamida Cell Presents Efficacy and Safety Results of Phase 3 Study of Omidubicel in Patients with Hematologic Malignancies at the 2021 TCT Meetings of ASTCT and CIBMTR
- Gamida Cell to Present Full Data from Phase 3 Study of Omidubicel at TCT, the Combined Transplantation and Cellular Therapy Meetings of ASTCT and CIBMTR
- Gamida Cell to Present at Upcoming January Investor Conferences
- Gamida Cell Announces Closing of $75 Million Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
- Gamida Cell Added to NASDAQ Biotechnology Index
- Gamida Cell Announces Pricing of $65 Million Public Offering of Ordinary Shares
- Gamida Cell Announces Launch of Public Offering of Ordinary Shares
- Gamida Cell Provides Regulatory Update on Biologics License Application for Omidubicel
More ▼
Key statistics
On Friday, Gamida Cell Ltd (GMDA:NMQ) closed at 9.36, -37.60% below its 52-week high of 15.00, set on Feb 10, 2021.
52-week range
Markit short selling activity
Open | 9.66 |
---|---|
High | 9.90 |
Low | 9.03 |
Bid | 9.55 |
Offer | 9.80 |
Previous close | 9.36 |
Average volume | 2.02m |
---|---|
Shares outstanding | 58.99m |
Free float | 38.45m |
P/E (TTM) | -- |
Market cap | 552.17m USD |
EPS (TTM) | -1.17 USD |
Data delayed at least 15 minutes, as of Feb 26 2021 21:00 GMT.
More ▼